<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03661567</url>
  </required_header>
  <id_info>
    <org_study_id>GASTO-1044</org_study_id>
    <nct_id>NCT03661567</nct_id>
  </id_info>
  <brief_title>Methylprednisolone After Split-course Chemoradiotherapy For Bulky Local Advanced None-small Cell Lung Cancer</brief_title>
  <official_title>A Prospective, Randomized, Controlled Phase Ⅱ Study of Preventively Use of Methylprednisolone After Split-course Chemoradiotherapy to Reduce the Risk of Radiation-induced Pulmonary Injury For Bulky Local Advanced None-small Cell Lung Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sun Yat-sen University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sun Yat-sen University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This Phase II randomized controlled study is to determine the efficacy of the preventively
      use of methylprednisolone after split-course chemoradiotherapy (CCRT) in locally advanced
      non-small cell lung cancer with bulky tumor.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is to determine the efficacy of the preventively use of methylprednisolone after
      split-course chemoradiotherapy(CCRT) in locally advanced non-small cell lung cancer with
      bulky tumor.

      All patients received four cycles of weekly docetaxel (25mg/㎡) and nedaplatin (25mg/㎡)(DP),
      each of 1 day's duration, combined with split-course thoracic radiotherapy, with one-month
      break. In the experimental arm, patients were treated with methylprednisolone after the first
      course of radiation, once a day, 32 milligram (mg) for 7 days, 24 mg for the next 7 days,then
      16mg for 7 days, and 8 mg for the last 7 days. Toxicities will be graded according to
      National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) v. 4.0.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 9, 2018</start_date>
  <completion_date type="Anticipated">September 2021</completion_date>
  <primary_completion_date type="Anticipated">September 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>rate of grade≥2 radiation pneumonia(NCI-CTC4.0)</measure>
    <time_frame>1 year from the end of radiotherapy</time_frame>
    <description>radiation-induced pulmonary injury is classified into 1-5 grades according to NCI-CTC4.0. The incidence of symptomatic radiation-induced pulmonary injury: the ratio of grade 2 and above radiation-induced pulmonary injury cases in 1 year after radio therapy to all cases can be evaluated .</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>the rate of grade≥2 pulmonary ventilation and diffusion capacity decline</measure>
    <time_frame>1 year from the end of radiotherapy</time_frame>
    <description>It is divided into grade 1-4 according to SOMA.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>the rate of grade≥2 visible change in CT after radiation</measure>
    <time_frame>1 year from the end of radiotherapy</time_frame>
    <description>It is divided into grade 1-4 according to SOMA.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">234</enrollment>
  <condition>Non-small Cell Lung Cancer</condition>
  <arm_group>
    <arm_group_label>Methylprednisolone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients were treated with methylprednisolone after the first course of chest radiation and concurrent chemotherapy, once a day, 32 milligram (mg) for 7 days, 24 mg for the next 7 days, then 16mg for 7 days, and 8 mg for the last 7 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Observation</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Observation after the first course of chest radiation, methylprednisolone can only be used for therapeutic purpose in the presence of grade≥2 radiation induced lung injury(NCI-CTC4.0).</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>chest radiation</intervention_name>
    <description>split-course chest radiation</description>
    <arm_group_label>Methylprednisolone</arm_group_label>
    <arm_group_label>Observation</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>concurrent chemotherapy</intervention_name>
    <description>weekly docetaxel(25mg/㎡) and nedaplatin(25mg/㎡) concurrent with chest radiation</description>
    <arm_group_label>Methylprednisolone</arm_group_label>
    <arm_group_label>Observation</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Methylprednisolone</intervention_name>
    <description>Methylprednisolone after the first course of radiation, once a day, 32 milligram (mg) for 7 days, 24 mg for the next 7 days, then 16mg for 7 days, and 8 mg for the last 7 days.</description>
    <arm_group_label>Methylprednisolone</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Pathologic confirmation of NSCLC.

          -  Patients have measurable or evaluable lesions based on the Response Evaluation
             Criteria in Solid Tumors (RECIST) criteria.

               -  Unresectable phase IIIA(N2) and IIIB lung cancer confirmed by PET/CT, CT or MRI.

               -  Whole lung V20&gt;=35% when giving 60Gy which is the minimum dose of radical
                  irradiation.

          -  Eastern Cooperative Oncology Group (ECOG) performance status 0-1.

          -  Previously treated with chemotherapy or treatment-naive

          -  No previous chest radiotherapy, immunotherapy or biotherapy

          -  Hemoglobin≥10 mg/dL, platelet≥100000/μL,absolute neutrophil count ≥1500/μL

          -  Serum creatinine ≤1.25 times the upper normal limit(UNL), or creatinine clearance≥60
             ml/min

          -  Bilirubin ≤1.5 times UNL, AST（SGOT）≤2.5 times UNL ,ALT（SGPT）≤2.5 times UNL,alkaline
             phosphatase ≤5 times UNL

          -  FEV1 &gt;0.8 L

          -  CB6 within normal limits

          -  patients and their family signed the informed consents

        Exclusion Criteria:

          -  Previous or recent another malignancy, except nonmelanoma skin cancer or cervical
             cancer in situ

          -  Contraindication for chemotherapy

          -  Malignant pleural or pericardial effusion.

          -  Women in pregnancy, lactation period, or no pregnancy test 14 days before the first
             dose

          -  Women who has the probability of pregnancy without contraception

          -  Tendency of hemorrhage

          -  In other clinical trials within 30 days

          -  Addicted in drugs or alcohol, AIDS patients

          -  Uncontrollable seizure or psychotic patients without self-control ability

          -  Severe allergy or idiosyncrasy

          -  Not suitable for this study judged by researchers
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hui Liu, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Sun Yat-sen University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Bo Qiu, Attending</last_name>
    <phone>+86-020-87343031</phone>
    <email>qiubo@sysucc.org.cn</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Hui liu, Professor</last_name>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Sun yat-sen University Cancer Center</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bo Qiu, Attending</last_name>
      <phone>+86-020-87343031</phone>
      <email>qiubo@sysucc.org.cn</email>
    </contact>
    <contact_backup>
      <last_name>Hui Liu, Professor</last_name>
    </contact_backup>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <reference>
    <citation>Giridhar P, Mallick S, Rath GK, Julka PK. Radiation induced lung injury: prediction, assessment and management. Asian Pac J Cancer Prev. 2015;16(7):2613-7. Review.</citation>
    <PMID>25854336</PMID>
  </reference>
  <reference>
    <citation>Marks LB, Bentzen SM, Deasy JO, Kong FM, Bradley JD, Vogelius IS, El Naqa I, Hubbs JL, Lebesque JV, Timmerman RD, Martel MK, Jackson A. Radiation dose-volume effects in the lung. Int J Radiat Oncol Biol Phys. 2010 Mar 1;76(3 Suppl):S70-6. doi: 10.1016/j.ijrobp.2009.06.091. Review.</citation>
    <PMID>20171521</PMID>
  </reference>
  <reference>
    <citation>Barthelemy-Brichant N, Bosquée L, Cataldo D, Corhay JL, Gustin M, Seidel L, Thiry A, Ghaye B, Nizet M, Albert A, Deneufbourg JM, Bartsch P, Nusgens B. Increased IL-6 and TGF-beta1 concentrations in bronchoalveolar lavage fluid associated with thoracic radiotherapy. Int J Radiat Oncol Biol Phys. 2004 Mar 1;58(3):758-67.</citation>
    <PMID>14967431</PMID>
  </reference>
  <reference>
    <citation>Trott KR, Herrmann T, Kasper M. Target cells in radiation pneumopathy. Int J Radiat Oncol Biol Phys. 2004 Feb 1;58(2):463-9.</citation>
    <PMID>14751516</PMID>
  </reference>
  <reference>
    <citation>Roberts CM, Foulcher E, Zaunders JJ, Bryant DH, Freund J, Cairns D, Penny R, Morgan GW, Breit SN. Radiation pneumonitis: a possible lymphocyte-mediated hypersensitivity reaction. Ann Intern Med. 1993 May 1;118(9):696-700.</citation>
    <PMID>8460855</PMID>
  </reference>
  <reference>
    <citation>Kainthola A, Haritwal T, Tiwari M, Gupta N, Parvez S, Tiwari M, Prakash H, Agrawala PK. Immunological Aspect of Radiation-Induced Pneumonitis, Current Treatment Strategies, and Future Prospects. Front Immunol. 2017 May 2;8:506. doi: 10.3389/fimmu.2017.00506. eCollection 2017. Review.</citation>
    <PMID>28512460</PMID>
  </reference>
  <reference>
    <citation>Murshed H, Liu HH, Liao Z, Barker JL, Wang X, Tucker SL, Chandra A, Guerrero T, Stevens C, Chang JY, Jeter M, Cox JD, Komaki R, Mohan R. Dose and volume reduction for normal lung using intensity-modulated radiotherapy for advanced-stage non-small-cell lung cancer. Int J Radiat Oncol Biol Phys. 2004 Mar 15;58(4):1258-67. Erratum in: Int J Radiat Oncol Biol Phys. 2004 Jul 1;59(3):921. Change, Joe T [corrected to Chang, Joe T].</citation>
    <PMID>15001271</PMID>
  </reference>
  <reference>
    <citation>Gielda BT, Marsh JC, Zusag TW, Faber LP, Liptay M, Basu S, Warren WH, Fidler MJ, Batus M, Abrams RA, Bonomi P. Split-course chemoradiotherapy for locally advanced non-small cell lung cancer: a single-institution experience of 144 patients. J Thorac Oncol. 2011 Jun;6(6):1079-86. doi: 10.1097/JTO.0b013e3182199a7c.</citation>
    <PMID>21532501</PMID>
  </reference>
  <reference>
    <citation>Li Y, Wang J, Tan L, Hui B, Ma X, Yan Y, Xue C, Shi X, Drokow EK, Ren J. Dosimetric comparison between IMRT and VMAT in irradiation for peripheral and central lung cancer. Oncol Lett. 2018 Mar;15(3):3735-3745. doi: 10.3892/ol.2018.7732. Epub 2018 Jan 4.</citation>
    <PMID>29467890</PMID>
  </reference>
  <reference>
    <citation>Spoelstra FO, Pantarotto JR, van Sörnsen de Koste JR, Slotman BJ, Senan S. Role of adaptive radiotherapy during concomitant chemoradiotherapy for lung cancer: analysis of data from a prospective clinical trial. Int J Radiat Oncol Biol Phys. 2009 Nov 15;75(4):1092-7. doi: 10.1016/j.ijrobp.2008.12.027. Epub 2009 Mar 26.</citation>
    <PMID>19327915</PMID>
  </reference>
  <reference>
    <citation>Inoue A, Kunitoh H, Sekine I, Sumi M, Tokuuye K, Saijo N. Radiation pneumonitis in lung cancer patients: a retrospective study of risk factors and the long-term prognosis. Int J Radiat Oncol Biol Phys. 2001 Mar 1;49(3):649-55.</citation>
    <PMID>11172945</PMID>
  </reference>
  <reference>
    <citation>Vogelius IR, Bentzen SM. A literature-based meta-analysis of clinical risk factors for development of radiation induced pneumonitis. Acta Oncol. 2012 Nov;51(8):975-83. doi: 10.3109/0284186X.2012.718093. Epub 2012 Sep 5. Review.</citation>
    <PMID>22950387</PMID>
  </reference>
  <reference>
    <citation>Wang LP, Wang YW, Wang BZ, Sun GM, Wang XY, Xu JL. Expression of interleukin-17A in lung tissues of irradiated mice and the influence of dexamethasone. ScientificWorldJournal. 2014 Mar 12;2014:251067. doi: 10.1155/2014/251067. eCollection 2014.</citation>
    <PMID>24744681</PMID>
  </reference>
  <reference>
    <citation>Kim S, Oh IJ, Park SY, Song JH, Seon HJ, Kim YH, Yoon SH, Yu JY, Lee BR, Kim KS, Kim YC. Corticosteroid therapy against treatment-related pulmonary toxicities in patients with lung cancer. J Thorac Dis. 2014 Sep;6(9):1209-17. doi: 10.3978/j.issn.2072-1439.2014.07.16.</citation>
    <PMID>25276362</PMID>
  </reference>
  <reference>
    <citation>Guilhem A, Celton B, Terminet A, Pavio C, Raschilas F, Blain H. [Radiation pneumonitis: a rare and potentially severe pneumonia. Usefulness of corticosteroids]. Rev Med Interne. 2010 Aug;31(8):e10-2. doi: 10.1016/j.revmed.2009.08.011. Epub 2010 Apr 21. French.</citation>
    <PMID>20413191</PMID>
  </reference>
  <reference>
    <citation>Sekine I, Sumi M, Ito Y, Nokihara H, Yamamoto N, Kunitoh H, Ohe Y, Kodama T, Saijo N, Tamura T. Retrospective analysis of steroid therapy for radiation-induced lung injury in lung cancer patients. Radiother Oncol. 2006 Jul;80(1):93-7. Epub 2006 Jul 3.</citation>
    <PMID>16820236</PMID>
  </reference>
  <verification_date>September 2018</verification_date>
  <study_first_submitted>September 1, 2018</study_first_submitted>
  <study_first_submitted_qc>September 5, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">September 7, 2018</study_first_posted>
  <last_update_submitted>September 6, 2018</last_update_submitted>
  <last_update_submitted_qc>September 6, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">September 10, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Sun Yat-sen University</investigator_affiliation>
    <investigator_full_name>Hui Liu</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>methylprednisolone</keyword>
  <keyword>Split-course Chemoradiotherapy</keyword>
  <keyword>Radiation-induced Pulmonary Injury</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Small Cell Lung Carcinoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Methylprednisolone</mesh_term>
    <mesh_term>Methylprednisolone Acetate</mesh_term>
    <mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
    <mesh_term>Prednisolone</mesh_term>
    <mesh_term>Prednisolone acetate</mesh_term>
    <mesh_term>Prednisolone hemisuccinate</mesh_term>
    <mesh_term>Prednisolone phosphate</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

